Cargando…

Endoplasmic Reticulum Stress Signaling as a Therapeutic Target in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a lethal cancer with limited treatment options. No targeted therapy has emerged yet. Here, we performed an integrated molecular characterization of patient tumors in the TCGA dataset, and discovered that endoplasmic reticulum (ER) stress and the adaptive unfol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Duo, Yang, Haitang, Yang, Zhang, Berezowska, Sabina, Gao, Yanyun, Liang, Shun-Qing, Marti, Thomas M., Hall, Sean R. R., Dorn, Patrick, Kocher, Gregor J., Schmid, Ralph A., Peng, Ren-Wang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827154/ https://www.ncbi.nlm.nih.gov/pubmed/31597321 http://dx.doi.org/10.3390/cancers11101502

Ejemplares similares

Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma
por: Xu, Duo, et al.
Publicado: (2018)

Malignant pleural mesothelioma co-opts BCL-X(L) and autophagy to escape apoptosis
por: Xu, Duo, et al.
Publicado: (2021)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2023)

Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2022)

Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
por: Xu, Duo, et al.
Publicado: (2020)

Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma
por: Karatkevich, Darya, et al.
Publicado: (2022)

Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2020)

NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
por: Yang, Haitang, et al.
Publicado: (2021)

Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
por: Wang, Limei, et al.
Publicado: (2021)

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)
por: Gao, Yanyun, et al.
Publicado: (2021)

Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines
por: Cortes-Dericks, Lourdes, et al.
Publicado: (2016)

Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?
por: Gao, Yanyun, et al.
Publicado: (2022)

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer
por: Yang, Haitang, et al.
Publicado: (2019)

Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature
por: Schumann, Sven Oliver, et al.
Publicado: (2021)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

Functional and molecular characterization of PD1(+) tumor-infiltrating lymphocytes from lung cancer patients
por: Lipp, Jesse J., et al.
Publicado: (2022)

The endoplasmic reticulum mitochondrial calcium cross talk is downregulated in malignant pleural mesothelioma cells and plays a critical role in apoptosis inhibition
por: Patergnani, Simone, et al.
Publicado: (2015)

Comment on “Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy”
por: Yang, Haitang, et al.
Publicado: (2020)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer
por: Yang, Zhang, et al.
Publicado: (2022)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Interleukin‐5‐producing malignant pleural mesothelioma with eosinophilic pleural effusion
por: Takeuchi, Eiji, et al.
Publicado: (2020)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
por: Cortes-Dericks, Lourdes, et al.
Publicado: (2017)

Blocking the epithelial-to-mesenchymal transition pathway abrogates resistance to anti-folate chemotherapy in lung cancer
por: Liang, S-Q, et al.
Publicado: (2015)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma in situ
por: Ando, Kohei, et al.
Publicado: (2022)

Targeting YAP in malignant pleural mesothelioma
por: Zhang, Wen‐Qian, et al.
Publicado: (2017)

Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Thoracoscopy in Pleural Malignant Mesothelioma Diagnosis
por: Tassi, G. F., et al.
Publicado: (1997)

Imaging in staging of malignant pleural mesothelioma
por: Truong, Mylene T, et al.
Publicado: (2004)

Hedgehog Signaling in Malignant Pleural Mesothelioma
por: Felley-Bosco, Emanuela, et al.
Publicado: (2015)

Multimodality treatment of malignant pleural mesothelioma
por: Berzenji, Lawek, et al.
Publicado: (2018)

Modern management of malignant pleural mesothelioma
por: Patel, Shivani C, et al.
Publicado: (2016)

Pleural tuberculosis mimicking malignant mesothelioma
por: Dawood, Wajahat, et al.
Publicado: (2019)

Cytomegalovirus infection in malignant pleural mesothelioma
por: Hunter-Schlichting, DeVon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c1q6opl84qs67ipjhvt5cfpoqc